Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for microvascular complication prevention in type 1 diabetes with high glycemic variability
2025-521397-34-00Phase 4Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of colchicine in diabetes mellitus type 1 (T1D), diabetic retinopathy (DR) and diabetic glomerulosclerosis, sponsored by Radboud University Medical Center. Planned start Oct 2025; status: authorised.
02
Drugs
colchicine
03
Conditions
diabetes mellitus type 1 (T1D)diabetic retinopathy (DR)diabetic glomerulosclerosis
Beyond the preview
Go deeper on 2025-521397-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521397-34-00.